- Kindred Biosciences Inc KIN has announced positive results from the pharmacokinetic study (KIND-039) evaluating a new long-acting interleukin (IL)-31 antibody.
- Results from the study demonstrated that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab, thus allowing for up to three-fold longer intervals between dosing.
- The company expects to initiate the pivotal study for this new molecule by the end of this year.
- The new long-acting IL-31 program is complementary to Kindred's tirnovetmab, an interleukin (IL)-31 targeting antibody currently in pivotal efficacy study for the treatment of atopic dermatitis in dogs.
- Price Action: KIN shares are up 6.2% higher at $5 in premarket trading on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
